 | • レポートコード：MRC23Q36314 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の放射性医薬品療法市場について調査・分析し、世界の放射性医薬品療法市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（アクチニウム-225、ルテチウム-177、ラジウム-223、ホルミウム-166、その他）、用途別セグメント分析（腫瘍学、循環器内科、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bracco Imaging、Bayer、Mallinckrodt、Nordion、Triad Isotopes、Lantheus、IBA Group、GE Healthcare、China Isotope & Radiation、Jubilant Pharma、Eli Lilly、Advanced Accelerator Applications、SIEMENS、Dongcheng、Navideaなどが含まれています。 世界の放射性医薬品療法市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、放射性医薬品療法市場規模を推定する際に考慮しました。本レポートは、放射性医薬品療法の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、放射性医薬品療法に関するビジネス上の意思決定に役立てることを目的としています。 ・放射性医薬品療法市場の概要 - 放射性医薬品療法のタイプ別セグメント - 世界の放射性医薬品療法市場規模：タイプ別分析（アクチニウム-225、ルテチウム-177、ラジウム-223、ホルミウム-166、その他） - 放射性医薬品療法の用途別セグメント - 世界の放射性医薬品療法市場規模：用途別分析（腫瘍学、循環器内科、その他） - 世界の放射性医薬品療法市場規模予測（2018年-2029年） ・放射性医薬品療法市場の成長トレンド - 放射性医薬品療法の地域別市場規模（2018年-2029年） - 放射性医薬品療法市場ダイナミクス - 放射性医薬品療法の業界動向 - 放射性医薬品療法市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：アクチニウム-225、ルテチウム-177、ラジウム-223、ホルミウム-166、その他 - 世界の放射性医薬品療法のタイプ別市場規模（2018年-2023年） - 世界の放射性医薬品療法のタイプ別市場規模（2024年-2029年） ・用途別セグメント：腫瘍学、循環器内科、その他 - 世界の放射性医薬品療法の用途別市場規模（2018年-2023年） - 世界の放射性医薬品療法の用途別市場規模（2024年-2029年） ・放射性医薬品療法の地域別市場規模 - 北米の放射性医薬品療法市場規模（2018年-2029年） - アメリカの放射性医薬品療法市場規模（2018年-2029年） - ヨーロッパの放射性医薬品療法市場規模（2018年-2029年） - アジア太平洋の放射性医薬品療法市場規模（2018年-2029年） - 中国の放射性医薬品療法市場規模（2018年-2029年） - 日本の放射性医薬品療法市場規模（2018年-2029年） - 韓国の放射性医薬品療法市場規模（2018年-2029年） - インドの放射性医薬品療法市場規模（2018年-2029年） - オーストラリアの放射性医薬品療法市場規模（2018年-2029年） - 中南米の放射性医薬品療法市場規模（2018年-2029年） - 中東・アフリカの放射性医薬品療法市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Bracco Imaging、Bayer、Mallinckrodt、Nordion、Triad Isotopes、Lantheus、IBA Group、GE Healthcare、China Isotope & Radiation、Jubilant Pharma、Eli Lilly、Advanced Accelerator Applications、SIEMENS、Dongcheng、Navidea ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Radiopharmaceutical Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Radiopharmaceutical Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Radiopharmaceutical Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Radiopharmaceutical Therapy in Oncology is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Radiopharmaceutical Therapy include Bracco Imaging, Bayer, Mallinckrodt, Nordion, Triad Isotopes, Lantheus, IBA Group, GE Healthcare and China Isotope & Radiation, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceutical Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceutical Therapy.
The Radiopharmaceutical Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Radiopharmaceutical Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radiopharmaceutical Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Segment by Type
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Segment by Application
Oncology
Cardiology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radiopharmaceutical Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radiopharmaceutical Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Actinium-225
1.2.3 Lutetium-177
1.2.4 Radium-223
1.2.5 Holmium-166
1.2.6 Other
1.3 Market by Application
1.3.1 Global Radiopharmaceutical Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radiopharmaceutical Therapy Market Perspective (2018-2029)
2.2 Radiopharmaceutical Therapy Growth Trends by Region
2.2.1 Global Radiopharmaceutical Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Radiopharmaceutical Therapy Historic Market Size by Region (2018-2023)
2.2.3 Radiopharmaceutical Therapy Forecasted Market Size by Region (2024-2029)
2.3 Radiopharmaceutical Therapy Market Dynamics
2.3.1 Radiopharmaceutical Therapy Industry Trends
2.3.2 Radiopharmaceutical Therapy Market Drivers
2.3.3 Radiopharmaceutical Therapy Market Challenges
2.3.4 Radiopharmaceutical Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radiopharmaceutical Therapy Players by Revenue
3.1.1 Global Top Radiopharmaceutical Therapy Players by Revenue (2018-2023)
3.1.2 Global Radiopharmaceutical Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Radiopharmaceutical Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radiopharmaceutical Therapy Revenue
3.4 Global Radiopharmaceutical Therapy Market Concentration Ratio
3.4.1 Global Radiopharmaceutical Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radiopharmaceutical Therapy Revenue in 2022
3.5 Radiopharmaceutical Therapy Key Players Head office and Area Served
3.6 Key Players Radiopharmaceutical Therapy Product Solution and Service
3.7 Date of Enter into Radiopharmaceutical Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radiopharmaceutical Therapy Breakdown Data by Type
4.1 Global Radiopharmaceutical Therapy Historic Market Size by Type (2018-2023)
4.2 Global Radiopharmaceutical Therapy Forecasted Market Size by Type (2024-2029)
5 Radiopharmaceutical Therapy Breakdown Data by Application
5.1 Global Radiopharmaceutical Therapy Historic Market Size by Application (2018-2023)
5.2 Global Radiopharmaceutical Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Radiopharmaceutical Therapy Market Size (2018-2029)
6.2 North America Radiopharmaceutical Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Radiopharmaceutical Therapy Market Size by Country (2018-2023)
6.4 North America Radiopharmaceutical Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radiopharmaceutical Therapy Market Size (2018-2029)
7.2 Europe Radiopharmaceutical Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Radiopharmaceutical Therapy Market Size by Country (2018-2023)
7.4 Europe Radiopharmaceutical Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radiopharmaceutical Therapy Market Size (2018-2029)
8.2 Asia-Pacific Radiopharmaceutical Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Radiopharmaceutical Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Radiopharmaceutical Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radiopharmaceutical Therapy Market Size (2018-2029)
9.2 Latin America Radiopharmaceutical Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Radiopharmaceutical Therapy Market Size by Country (2018-2023)
9.4 Latin America Radiopharmaceutical Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radiopharmaceutical Therapy Market Size (2018-2029)
10.2 Middle East & Africa Radiopharmaceutical Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Radiopharmaceutical Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Radiopharmaceutical Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bracco Imaging
11.1.1 Bracco Imaging Company Detail
11.1.2 Bracco Imaging Business Overview
11.1.3 Bracco Imaging Radiopharmaceutical Therapy Introduction
11.1.4 Bracco Imaging Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.1.5 Bracco Imaging Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Radiopharmaceutical Therapy Introduction
11.2.4 Bayer Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.2.5 Bayer Recent Development
11.3 Mallinckrodt
11.3.1 Mallinckrodt Company Detail
11.3.2 Mallinckrodt Business Overview
11.3.3 Mallinckrodt Radiopharmaceutical Therapy Introduction
11.3.4 Mallinckrodt Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.3.5 Mallinckrodt Recent Development
11.4 Nordion
11.4.1 Nordion Company Detail
11.4.2 Nordion Business Overview
11.4.3 Nordion Radiopharmaceutical Therapy Introduction
11.4.4 Nordion Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.4.5 Nordion Recent Development
11.5 Triad Isotopes
11.5.1 Triad Isotopes Company Detail
11.5.2 Triad Isotopes Business Overview
11.5.3 Triad Isotopes Radiopharmaceutical Therapy Introduction
11.5.4 Triad Isotopes Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.5.5 Triad Isotopes Recent Development
11.6 Lantheus
11.6.1 Lantheus Company Detail
11.6.2 Lantheus Business Overview
11.6.3 Lantheus Radiopharmaceutical Therapy Introduction
11.6.4 Lantheus Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.6.5 Lantheus Recent Development
11.7 IBA Group
11.7.1 IBA Group Company Detail
11.7.2 IBA Group Business Overview
11.7.3 IBA Group Radiopharmaceutical Therapy Introduction
11.7.4 IBA Group Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.7.5 IBA Group Recent Development
11.8 GE Healthcare
11.8.1 GE Healthcare Company Detail
11.8.2 GE Healthcare Business Overview
11.8.3 GE Healthcare Radiopharmaceutical Therapy Introduction
11.8.4 GE Healthcare Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.8.5 GE Healthcare Recent Development
11.9 China Isotope & Radiation
11.9.1 China Isotope & Radiation Company Detail
11.9.2 China Isotope & Radiation Business Overview
11.9.3 China Isotope & Radiation Radiopharmaceutical Therapy Introduction
11.9.4 China Isotope & Radiation Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.9.5 China Isotope & Radiation Recent Development
11.10 Jubilant Pharma
11.10.1 Jubilant Pharma Company Detail
11.10.2 Jubilant Pharma Business Overview
11.10.3 Jubilant Pharma Radiopharmaceutical Therapy Introduction
11.10.4 Jubilant Pharma Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.10.5 Jubilant Pharma Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Detail
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly Radiopharmaceutical Therapy Introduction
11.11.4 Eli Lilly Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.11.5 Eli Lilly Recent Development
11.12 Advanced Accelerator Applications
11.12.1 Advanced Accelerator Applications Company Detail
11.12.2 Advanced Accelerator Applications Business Overview
11.12.3 Advanced Accelerator Applications Radiopharmaceutical Therapy Introduction
11.12.4 Advanced Accelerator Applications Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.12.5 Advanced Accelerator Applications Recent Development
11.13 SIEMENS
11.13.1 SIEMENS Company Detail
11.13.2 SIEMENS Business Overview
11.13.3 SIEMENS Radiopharmaceutical Therapy Introduction
11.13.4 SIEMENS Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.13.5 SIEMENS Recent Development
11.14 Dongcheng
11.14.1 Dongcheng Company Detail
11.14.2 Dongcheng Business Overview
11.14.3 Dongcheng Radiopharmaceutical Therapy Introduction
11.14.4 Dongcheng Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.14.5 Dongcheng Recent Development
11.15 Navidea
11.15.1 Navidea Company Detail
11.15.2 Navidea Business Overview
11.15.3 Navidea Radiopharmaceutical Therapy Introduction
11.15.4 Navidea Revenue in Radiopharmaceutical Therapy Business (2018-2023)
11.15.5 Navidea Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details